Solid-state characterization of Jiegeng Zhihuang Powder prior to application selection is not a quality-control formality; it is the primary determinant of which downstream veterinary dosage route will survive process validation. The API is a multi-component botanical extract, not a single chemical entity, and its conversion into tablets, injections, capsules, granules, premix, or drinking-water solutions is governed by hygroscopicity, particle-size distribution, flow index, aqueous dispersion behavior, and thermolability. A supplier lot with loss on drying above 6.0% according to USP 731 and water content above 5.0% by Karl Fischer titration per USP 921 is normally diverted away from direct compression and high-speed capsule filling because excess surface moisture depresses the glass transition of amorphous extract domains, producing punch adhesion, picking, and erratic fill weights. The as-received powder should additionally be characterized for bulk and tapped density using USP 616 and for flow by USP 1174 or EP 2.9.36. A Carr index above 25% or Hausner ratio above 1.25 places the lot in the poor-flow category under the cited methods, which forces the formulator to select a granulation step or to modify particle surfaces with hydrophobic colloidal silica. Sieve analysis by air-jet sieving or laser diffraction per ISO 13320 identifies the coarse fibrous fraction that can cause content non-uniformity in low-dose mixtures. These measurements are not only for incoming raw material release; they define the boundary between a robust commercial process and a batch that will fail during scale-up on a rotary tablet press or tamping-pin capsule machine.

When Tablet Compression Reaches the Punch-Sticking Threshold

Tablet and bolus manufacturers working with botanical extracts encounter two process conflicts: poor powder flow and time-dependent punch sticking. Jiegeng Zhihuang Powder that has not been granulated generally cannot be compressed at commercial speed because cohesive fines segregate in the feed frame and create weight variation beyond the acceptance value limit of 15 under USP 905. Wet granulation with a binder such as pregelatinized starch at 3–5% w/w or povidone K30 at 2–4% w/w is the standard correction; the granulation liquid is added in a high-shear granulator or planetary mixer until the end granule reaches a d50 of 100–250 µm. The wet mass is dried in a fluid-bed dryer at an inlet air temperature below 60°C, because polysaccharide-rich extract fractions depolymerize and darken at excess temperature. After drying, the granulate is milled through an oscillating granulator fitted with a 1.0 mm screen and blended with 0.5–1.0% w/w magnesium stearate. Compression is performed on a rotary tablet press equipped with a precompression roller; precompression force is set at 2–4 kN to expel entrapped air, while main compression force is adjusted until tablet hardness yields friability not more than 1.0% under USP 1216. The process environment must be controlled below 40% relative humidity and, where possible, with a dew point below 4°C; sustained humidity above 50% RH is the most common cause of picking and sticking on 10-station and 16-station production presses. Finished tablets should be tested for disintegration by USP 701; a non-enteric veterinary bolus should disintegrate within 30 min in water at 37°C, although formulations with high lubricant content can exceed this when over-blended. For oral respiratory-support tablets in pigs and cattle, total aerobic microbial count should be controlled by USP 61 and specified pathogens by USP 62; a common nonsterile oral limit is not more than 10⁴ CFU/g for total aerobic microbial count, but registered specifications may differ by jurisdiction and target species.

A sterile route from the same raw powder is a filtration engineering problem, not a simple dissolution exercise. The extract contains water-soluble and water-dispersible fractions that do not form a true solution; colloidal polysaccharides and polyphenolic complexes generate membrane fouling. The bulk solution is prepared in Water for Injection at 35–40°C using a high-shear mixer to hydrate the powder, then adjusted to pH 5.5–6.5 with a citrate or phosphate buffer system. Clarification is carried out sequentially through a 0.45 µm polyethersulfone prefilter and a 0.22 µm sterilizing-grade membrane meeting ASTM F838-20 for bacterial retention. Filter capacity is the main scale-up constraint; published data for this specific botanical configuration is limited, so each batch must be preceded by a filterability trial that records volumetric throughput per 10-inch cartridge and pressure rise across the membrane. Endotoxin is a separate risk: botanical raw materials are not intrinsically pyrogen-free, and terminal steam sterilization does not remove lipopolysaccharide. The filtered bulk should be tested by a chromogenic limulus amebocyte lysate method conforming to USP 85, and the acceptance limit must be derived from the maximum intended dose and animal species, not copied from a human monogastric limit. The finished solution is filled aseptically in a Grade A zone with Grade B background according to EU GMP Annex 1; filter integrity is confirmed by bubble point or diffusion test before and after filling. Container closure should be amber borosilicate glass vials with chlorobutyl rubber stoppers to limit light-induced oxidation of polyphenolic fractions and to reduce sorption losses. Particulate matter is tested using USP 788 Method 1; for small-volume injectables, the limits are not more than 6000 particles per container at ≥10 µm and not more than 600 particles per container at ≥25 µm. Finished product should meet sterility under USP 71 and should be held for 14-day sterility test completion before release.

Does Capsule Filling Require Prior Dry Granulation When Carr Index Exceeds 30?

Hard gelatin and hydroxypropyl methylcellulose capsules for companion animal use expose the powder to two separate failure modes: powder flowing into the capsule body and moisture transfer into the shell. For a botanical extract with Carr index above 30%, direct encapsulation on a tamping-pin machine typically produces unacceptable weight variation because the powder bed does not densify uniformly. Dry granulation by roller compaction is preferred before encapsulation. The powder is compacted between rolls at a hydraulic pressure sufficient to produce ribbon density in the range of 0.7–1.0 g/cm³, then milled through a granulator screen of 0.8–1.2 mm. The resulting granulate is screened; the fraction between 75 µm and 850 µm should represent at least 80% of the batch to permit stable capsule filling. A dosator-type machine may handle the resulting granulate better than a tamping-pin machine when the granulate has residual electrostatic charge; dosator chamber diameter and compression setting must be adjusted so that fill weight variation remains within the USP 905 acceptance value of 15. Granulate moisture should be below 4.0% by USP 731 before filling, because residual water above 5.0% can cause gelatin crosslinking in hard gelatin shells and brittleness in HPMC shells. The filled capsules should be tested for disintegration per USP 701; for companion animal formulations, the target is usually complete disintegration within 30 min in 0.1 N hydrochloric acid at 37°C. If the product is intended for dogs or cats, palatability masking is carried out by adding a seal-coat or by encapsulating the granulate with a pH-sensitive polymer as an off-line step, but this coating must not delay marker release beyond the registered dissolution specification. Content uniformity and marker assay by HPLC are used to confirm that dry granulation did not segregate the botanical marker from the carrier.

Wet Granulation, Fluid-Bed Drying and Oral Powder Bag-Filling Constraints

Oral powders and granules for feed top dressing or sachet dosing are manufactured where direct mixing cannot overcome dusting, segregation, and poor wetting. A typical fluid-bed process uses a top-spray granulator to convert the raw powder and a dextrose monohydrate or lactose monohydrate carrier into a free-flowing granulate. Binder solution is prepared as povidone K30 at 2–5% dissolved in purified water and sprayed at a rate that maintains product temperature between 35°C and 45°C; inlet air temperature is set at 60–70°C, and atomization air pressure is kept at 1.5–2.5 bar. The wet mass is dried to loss on drying below 4.0% by USP 731, then passed through an oscillating granulator or screen mill to remove oversized agglomerates. The target granule distribution for sachet and bottle filling is 75–850 µm, with fines below 75 µm limited to ≤15%, because botanical extract fines carry electrostatic charge and adhere to polyolefin packaging walls. Bulk density should be controlled between 0.45 g/cm³ and 0.70 g/cm³ to match volumetric filler settings; final powder is packaged in aluminum-foil/polyethylene laminate sachets if the product will be exposed to ambient relative humidity above 60%. During process validation, the granulator is challenged for spray nozzle blockage, because extract polysaccharides can build up on the nozzle tip when binder flow is interrupted. The final oral powder must meet nonsterile microbial limits under USP 61 and USP 62; a typical veterinary oral powder specification limits total aerobic microbial count to not more than 10⁴ CFU/g and total combined yeast and mold count to not more than 10² CFU/g. Sieve analysis is performed by air-jet sieving per EP 2.9.12 to verify batch-to-batch consistency.

Feed Mill Premix Segregation Is Controlled by Carrier Selection, Not API Potency

Premix conversion for medicated feed is a dilution process, and the technical risk lies in particle-size mismatch and moisture transfer, not in active marker concentration. The raw Jiegeng Zhihuang Powder is added to a carrier such as ground rice hulls, wheat middlings, or calcium carbonate; the carrier choice depends on the target final feed inclusion and mineral compatibility of the complete feed. Ground rice hulls are suitable for low-density, fiber-bearing premixes, whereas calcium carbonate is used only when the complete feed can tolerate its alkalinity and when the botanical polyphenolic fraction will not chelate or discolor in the presence of calcium. Mixing is performed in a ribbon blender or double-ribbon mixer with a validated mixing time; the active marker should be assayed at multiple sampling points according to ISO 6497:2002 or an equivalent feed-sampling standard. Blend uniformity is acceptable when the coefficient of variation for marker content is below 5.0%; values above 10% indicate segregation or dead zones in the mixer. The premix should be sieved before final discharge; a screen aperture between 850 µm and 1.4 mm removes hard agglomerates. If the premix is stored before delivery, it should be kept below 25°C and below 60% relative humidity; choline chloride, hydrated trace minerals, and molassed ingredients must be separated from the botanical fraction because they introduce local moisture and can accelerate clumping and microbial growth. Carryover between batches is managed by cleaning validation using a marker assay after a flush with ground corn or rice hulls; the residual marker limit must comply with the facility's medicated feed procedures under FDA 21 CFR 225 or the receiving country's equivalent medicated feed GMP. The premix is intended for final feed incorporation at a rate derived from marker assay and target dose, generally in the range of 0.5–5.0 kg premix per tonne of finished feed for concentrate premixes, but the exact rate is registration-specific.

Farm water chemistry, not reconstitution temperature, determines whether a water-dispersion strategy is viable. The powder is not a fully water-soluble chemical; it forms a suspension or partial solution, so drinking-water application requires a two-phase approach. A stock suspension is prepared at 10% w/v in a polypropylene or high-density polyethylene tank using a mechanical stirrer at 500–1000 rpm for 10–15 min; the stock is then metered into the drinking line at a rate calibrated by marker concentration in the final water. Before installation, farm water should be tested for pH, total hardness, chlorine residual, and iron content. Hard water above 200 mg/L as CaCO₃ can reduce visual clarity and increase sediment because divalent ions interact with anionic polysaccharide and polyphenolic fractions; this does not necessarily abolish efficacy, but it changes the filtration requirement. A 100 µm Y-strainer or in-line filter should be installed before the dosing pump to protect nipple drinkers from clogging. The stock suspension should be prepared fresh every 24 h and protected from direct sunlight; residual chlorine above 2 ppm is to be avoided because oxidative modification of the extract can alter color and marker content. The pH of the final medicated water should be kept between 5.0 and 7.0; deliberate acidification below 4.0 can precipitate polyphenolic components and produce line sediment. During field trials, delivered dose is verified by sampling at the end of the drinker line and assaying the marker compound by HPLC; published data for this specific botanical configuration under farm hardness conditions is limited, so a pilot-scale compatibility test with target farm water is recommended before full flock or herd administration. The water line should be flushed after treatment to minimize biofilm accumulation on pipe surfaces, and the holding tank should be cleaned with an approved alkaline detergent followed by citric acid rinse.